Advantages and disadvantages of combination treatment with antipsychotics. ECNP Consensus Meeting, March 2008, Nice

European Neuropsychopharmacology

Volumn 19, Issue 7, 2009, Pages 520-532

  Goodwin, Guy ^a   Fleischhacker, Wolfgang ^b   Arango, Celso ^c   Baumann, Pierre ^d   Davidson, Michael ^e   de Hert, Marc ^f   Falkai, Peter ^g   Kapur, Shitij ^h   Leucht, Stefan ⁱ   Licht, Rasmus ^j   Naber, Dieter ^k   O'Keane, Veronica ^l   Papakostas, George ^m   Vieta, Eduard ⁿ   Zohar, Joseph ^o  

^a WARNEFORD HOSPITAL   (United Kingdom)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

^e TEL AVIV UNIVERSITY   (Israel)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g UNIVERSITY OF GÖTTINGEN   (Germany)

^h KING'S COLLEGE LONDON   (United Kingdom)

ⁱ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^j AARHUS UNIVERSITY HOSPITAL   (Denmark)

^k UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^l ST JAMES S HOSPITAL   (Ireland)

^m MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁿ UNIVERSITY OF BARCELONA   (Spain)

^o SHEBA MEDICAL CENTER   (Israel)

more..

Author keywords

Anticonvulsants; Antidepressants; Antipsychotics; Major depression; Mania; Mood stabilizers; Obsessive compulsive disorder (OCD); Polypharmacy; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; FLUVOXAMINE; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; VALPROIC ACID; ZIPRASIDONE;

ARTICLE; BIPOLAR DISORDER; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LONG TERM CARE; MAJOR DEPRESSION; MANIA; MONOTHERAPY; PRIORITY JOURNAL; PSYCHOSIS; RELAPSE; RISK FACTOR; SCHIZOPHRENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; MENTAL DISORDERS;

EID: 67349176083     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2009.04.003     Document Type: Article

References (83)

1. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am. J. Psychiatr. 159 4 Suppl (2002) 1-50
2. Basan A., Kissling W., and Leucht S. Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials. Schizophr. Res. 70 1 (2004) 33-37
3. Baumann P., Hiemke C., Ulrich S., Eckermann G., Gaertner I., Gerlach M., Kuss H.J., Laux G., Muller-Oerlinghausen B., Rao M.L., Riederer P., and Zernig G. The AGNP-TDM expert group consensus guidelines: Therapeutic Drug Monitoring in psychiatry. Pharmacopsychiatry 37 6 (2004) 243-265
4. Besag F.M.C., and Berry D. Interactions between antiepileptic and antipsychotic drugs. Drug Safety 29 2 (2006) 95-118
5. Bloch M.H., Landeros-Weisenberger A., Kelmendi B., Coric V., Bracken M.B., and Leckman J.F. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol. Psychiatry 11 7 (2006) 622-632
6. Bobes J., Arango C., Aranda P., Carmena R., Garcia-Garcia M., and Rejas J. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr. Res. 90 1-3 (2007) 162-173
7. Brambilla P., Barale F., Caverzasi E., Tognoni G., and Barbui C. Clozapine-treated subjects with treatment-resistant schizophrenia: a systematic review of experimental and observational studies. Int. Clin. Psychopharmacol. 17 4 (2002) 189-195
8. Brown C.S., Farmer R.G., Soberman J.E., and Eichner S.F. Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs. Clin. Pharmacokinet. 43 1 (2004) 33-56
9. Cincotta A.H., Gaziano J.M., Ezrokhi M., and Scranton R. Cycloset (Quick-Release Bromocriptine Mesylate), a novel centrally acting treatment for type 2 diabetes. Diabetologia 51 (2008) S22
10. Citrome L., Jaffe A., Levine J., Allingham B., and Robinson J. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr. Serv. 55 9 (2004) 1006-1013
11. Correll C.U. Antipsychotic polypharmacy, Part 2: why use 2 antipsychotics when 1 is not good enough?. J. Clin. Psychiatry 69 5 (2008) 860-861
12. Correll C.U., and Schenk E.M. Tardive dyskinesia and new antipsychotics. Curr. Opin. Psychiatry 21 2 (2008) 151-156
13. Correll C.U., Frederickson A.M., Kane J.M., and Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome?. Schizophr. Res. 89 1-3 (2007) 91-100
14. Correll C.U., Rummel-Kluge C., Kane J.M., and Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr. Bull. 35 2 (2009) 443-457
15. Dahl M.L. Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics-useful aid to prescribing?. Clin. Pharmacokinet. 41 7 (2002) 453-470
16. de Haan L., Lavalaye J., Linszen D., Dingemans P.M.A.J., and Booij J. Subjective experience and striatal dopamine D-2 receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. Am. J. Psychiatr. 157 6 (2000) 1019-1020
17. De Hert M., Kalnicka D., van Winkel R., Wampers M., Hanssens L., Van Eyck D., Scheen A., and Peuskens J. Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry 67 12 (2006) 1889-1896
18. De Hert M., Wampers M., and Peuskens J. Pharmacological treatment of hospitalised schizophrenic patients in Belgium. Int. J. Psychiatry Clin. Pract. 10 4 (2006) 285-290
19. De Hert M., Wampers M., van Winkel R., and Peuskens J. Anticholinergic use in hospitalised schizophrenic patients in Belgium. Psychiatry Res. 152 2-3 (2007) 165-172
20. Derry S., and Moore R.A. Atypical antipsychotics in bipolar disorder: systematic review of randomised trials. Bmc Psychiatry 7 (2007)
21. Ebinger M., and Uhr M. ABC drug transporter at the blood-brain barrier-effects on drug metabolism and drug response. Eur. Arch. Psychiatry Clin. Neurosci. 256 5 (2006) 294-298
22. Edlinger M., Hausmann A., Kemmler G., Kurz M., Kurzthaler I., Walch T., Walpoth M., and Fleischhacker W.W. Trends in the pharmacological treatment of patients with schizophrenia over a 12 year observation period. Schizophr. Res. 77 1 (2005) 25-34
23. Eisen J.L., Rasmussen S.A., Phillips K.A., Price L.H., Davidson J., Lydiard R.B., Ninan P., and Piggott T. Insight and treatment outcome in obsessive-compulsive disorder. Compr. Psychiatry 42 6 (2001) 494-497
24. Fleischhacker W.W., and Kahn R.S. Effectiveness of antipsychotic drugs in first episode schizophrenia and schizophreniform disorder. Schizophr. Res. 102 supplement 2 (2008) 48
25. Fleischhacker W.W., Heikkinen M.E., Olie J.P., Landsberg W., Dewaele P., McQuade R., and Hennicken D. Weight change on aripiprazole-clozapine combination in schizophrenic patients with weight gain and suboptimal response on clozapine: 16-week double-blind study. Eur. Psychiatr. 23 (2008) S114-S115
26. Fraguas D., Merchan-Naranjo J., Laita P., Parellada M., Moreno D., Ruiz-Sancho A., Cifuentes A., Giraldez M., and Arango C. Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. J. Clin. Psychiatry 69 7 (2008) 1166-1175
27. Frangou S., Donaldson S., Hadjulis M., Landau S., and Goldstein L.H. The Maudsley Bipolar Disorder Project: executive dysfunction in bipolar disorder I and its clinical correlates. Biol. Psychiatry 58 11 (2005) 859-864
28. Henderson D.C., Kunkel L., Nguyen D.D., Borba C.P., Daley T.B., Louie P.M., Freudenreich O., Cather C., Evins A.E., and Goff D.C. An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr. Scand. 113 2 (2006) 142-147
29. Hiemke C., Weigmann H., Hartter S., Dahmen N., Wetzel H., and Muller H. Elevated levels of clozapine in serum after addition of fluvoxamine. J. Clin. Psychopharmacol. 14 4 (1994) 279-281
30. Hollander E. Anxiety and OC spectrum disorders over life cycle. Int. J. Psychiatry Clin. Pract. 11 (2007) 5-10
31. Honer W.G., Thornton A.E., Chen E.Y.H., Chan R.C.K., Wong J.O.Y., Bergmann A., Falkai P., Pomarol-Clotet E., McKenna P.J., Stip E., Williams R., MacEwan G.W., Wasan K., Procyshyn R., Leung S.P., Wong J.O.Y., Rodriguez J.P., Lalonde P., Stip E., Pomarol-Clotet E., McKenna P.J., MacEwan G.W., Chen E.Y.H., Chan R.C.K., Flynn S.W., Altman S., Honer W.G., Thornton A.E., Procyshyn R., Huckin S., Au T., Boudreau A., Humphries B., Williams R., Wasan K., Bergmann A., Falkai P., Wobrock T., and Wollny H. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N. Engl. J. Med. 354 5 (2006) 472-482
32. Hummer M., and Huber J. Hyperprolactinaemia and antipsychotic therapy in schizophrenia. Curr. Med. Res. Opin. 20 2 (2004) 189-197
33. Hummer M., Malik P., Gasser R.W., Hofer A., Kemmler G., Naveda R.C.M., Rettenbacher M.A., and Fleischhacker W.W. Osteoporosis in patients with schizophrenia. Am. J. Psychiatr. 162 1 (2005) 162-167
34. Ingelman-Sundberg M. Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn-Schmiedebergs Archives of Pharmacology 369 1 (2004) 89-104
35. Josiassen R.C., Joseph A., Kohegyi E., Stokes S., Dadvand M., Paing W.W., and Shaughnessy R.A. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am. J. Psychiatr. 162 1 (2005) 130-136
36. Kane J.M. An evidence-based strategy for remission in schizophrenia. J. Clin. Psychiatry 69 (2008) 25-30
37. Kane J.A., Leucht S., Carpenter D., and Docherty J.P. Expert consensus guideline series-optimizing pharmacologic treatment of psychotic disorders-Introduction: Methods, commentary, and summary. J. Clin. Psychiatry 64 (2003) 5-97
38. Kapur S., Mizrahi R., and Agid O. Linking dopamine to salience to the subjective experience of patients with psychosis and antipsychotics. Int. J. Neuropsychopharmacol. 9 (2006) S85
39. Keck P.-E.J., McElroy S.L., Strakowski S.M., and Soutullo C.A. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. J. Clin. Psychiatry 61 Suppl 4 (2000) 33-38
40. Kennedy M.A., Roberts R.L., Mulder R.T., and Joyce P.R. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Am. J. Hum. Genet. 69 4 (2001) 581
41. Khan A., Schwartz K., Redding N., Kolts R.L., and Brown W.A. Psychiatric diagnosis and clinical trial completion rates: analysis of the FDA SBA reports. Neuropsychopharmacology 32 11 (2007) 2422-2430
42. Kirchheiner J., Nickchen K., Bauer M., Wong M.L., Licinio J., Roots I., and Brockmoller J. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry 9 5 (2004) 442-473
43. Kishimoto T., Watanabe K., Shimada N., Makita K., Yagi G., and Kashima H. Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. J. Clin. Psychiatry 69 3 (2008) 385-391
44. Kordon A., Wahl K., Koch N., Zurowski B., Anlauf M., Vielhaber K., Kahl K.G., Broocks A., Voderholzer U., and Hohagen F. Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study. J. Clin. Psychopharmacol. 28 5 (2008) 550-554
45. Leucht S., Corves C., Arbter D., Engel R.R., Li C.B., and Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373 9657 (2009) 31-41
46. Licht R.W., Gouliaev G., Vestergaard P., and Frydenberg M. Generalisability of results from randomised drug trials-a trial on antimanic treatment. Br. J. Psychiatry 170 (1997) 264-267
47. Linnet K., and Ejsing T.B. A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs. Eur. Neuropsychopharmacol. 18 3 (2008) 157-169
48. Marzolini C., Paus E., Buclin T., and Kim R.B. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. 75 1 (2004) 13-33
49. Mauri M.C., Volonteri L.S., Colasanti A., Fiorentini A., De Gaspari I.F., and Bareggi S.R. Clinical pharmacokinetics of atypical antipsychotics-a critical review of the relationship between plasma concentrations and clinical response. Clin. Pharmacokinet. 46 5 (2007) 359-388
50. Meaney A.M., and O Keane V. Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables. Schizophr. Res. 93 1-3 (2007) 136-143
51. Melander H., Salmonson T., Abadie E., and van Zwieten-Boot B. A regulatory Apologia-a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur. Neuropsychopharmacol. 18 9 (2008) 623-627
52. Meltzer H.Y. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21 2 (1999) S106-S115
53. Mizrahi R., Rusjan P., Agid O., Graff A., Mamo D.C., Zipursky R.B., and Kapur S. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D-2 receptors: a PET study in schizophrenia. Am. J. Psychiatry 164 4 (2007) 630-637
54. Moller H.J. Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 27 7 (2003) 1101-1111
55. Muller-Oerlinghausen B., Retzow A., Henn F.A., Giedke H., and Walden J. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group. J. Clin. Psychopharmacol. 20 2 (2000) 195-203
56. Murray M. Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents. J. Pharm. Pharmacol. 58 7 (2006) 871-885
57. Papakostas G.I., and Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur. Neuropsychopharmacol. 19 1 (2009) 2505-2513
58. Papakostas G.I., Shelton R.C., Smith J., and Fava M. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J. Clin. Psychiatry 68 6 (2007) 826-831
59. Paton C., Whittington C., and Barnes T.R. Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine-a meta-analysis. J. Clin. Psychopharmacol. 27 2 (2007) 198-204
60. Paton C., Barnes T.R.E., Cavanagh M.R., Taylor D., and Lelliott P. High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing. Br. J. Psychiatry 192 6 (2008) 435-439
61. Perlis R.H., Welge J.A., Vornik L.A., Hirschfeld R.M.A., and Keck P.E. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J. Clin. Psychiatry 67 4 (2006) 509-516
62. Preskorn S.H., and Jerkovich G.S. Central-nervous-system toxicity of tricyclic antidepressants-phenomenology, course, risk-factors, and role of therapeutic drug-monitoring. J. Clin. Psychopharmacol. 10 2 (1990) 88-95
63. Prior T.I., and Baker G.B. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J. Psychiatry Neurosci. 28 2 (2003) 99-112
64. Rapaport M.H., Gharabawi G.M., Canuso C.M., Mahmoud R.A., Keller M.B., Bossie C.A., Turkoz I., Lasser R.A., Loescher A., Bouhours P., Dunbar F., and Nemeroff C.B. Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 31 11 (2006) 2505-2513
65. Rittmannsberger H., Meise U., Schauflinger K., Horvath E., Donat H., and Hinterhuber H. Polypharmacy in psychiatric treatment. Patterns of psychotropic drug use in Austrian psychiatric clinics. Eur. Psychiatry 14 1 (1999) 33-40
66. Sachs G.S., and Gardner-Schuster E.E. Adjunctive treatment of acute mania: a clinical overview. Acta Psychiatr. Scand. 116 (2007) 27-34
67. Scranton R.E., Farwell W., Ezrokhi M., Gaziano J.M., and Cincotta A.H. Quick release bromocriptine (Cycloset (TM)) improves glycaemic control in patients with diabetes failing metformin/sulfonylurea combination therapy. Diabetologia 51 (2008) S372-S373
68. Shiloh R., Zemishlany Z., Aizenberg D., Radwan M., Schwartz B., Dorfman-Etrog P., Modai I., Khaikin M., and Weizman A. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine-a double-blind, placebo-controlled study. Br. J. Psychiatry 171 (1997) 569-573
69. Shim J.C., Shin J.G.K., Kelly D.L., Jung D.U., Seo Y.S., Liu K.H., Shon J.H., and Conley R.R. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for anti psychotic-induced hyperprolactinemia: a placebo-controlled trial. Am. J. Psychiatry 164 9 (2007) 1404-1410
70. Smith L.A., Cornelius V., Warnock A., Tacchi M.J., and Taylor D. Acute bipolar mania: a systematic review and meta-analysis of co-therapy vs. monotherapy. Acta Psychiatr. Scand. 115 1 (2007) 12-20
71. Spina E., and de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic & Clinical Pharmacology & Toxicology 100 1 (2007) 4-22
72. Suppes T., Vieta E., Liu S., Brecher M., Paulsson B., and Trial 127 Investigators. Maintenance Treatment for Patients With Bipolar I Disorder: Results From a North American Study of Quetiapine in Combination With Lithium or Divalproex (Trial 127). American Journal Psychiatry in Advance 166 (2009) 476-488 doi:10.1176/appi.ajp.2008.08020189 (Published March 16, 2009)
73. Tohen M., Chengappa K.N.R., Suppes T., Baker R.W., Zarate C.A., Bowden C.L., Sachs G.S., Kupfer D.J., Ghaemi S.N., Feldman P.D., Risser R.C., Evans A.R., and Calabrese J.R. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br. J. Psychiatry 184 (2004) 337-345
74. Tohen M., Bowden C.L., Smulevich A.B., Bergstrom R., Quinlan T., Osuntokun O., Wang W.V., Oliff H.S., Martenyi F., Kryzhanovskaya L.A., and Greil W. Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes. Br. J. Psychiatry 192 2 (2008) 135-143
75. Torrent C., Amann B., Sanchez-Moreno J.S., Colom F., Reinares M., Comes M., Rosa A.R., Scott J., and Vieta E. Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. Acta Psychiatr. Scand. 118 1 (2008) 4-18
76. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., Norquist G., Howland R.H., Lebowitz B., McGrath P.J., Shores-Wilson K., Biggs M.M., Balasubramani G.K., and Fava M. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 163 1 (2006) 28-40
77. Vieta E., Panicali F., Goetz I., Reed C., Comes M., and Tohen M. Olanzapine monotherapy and olanzapine combination therapy in the treatment of mania: 12-week results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) observational study. J. Affect. Disord. 106 1-2 (2008) 63-72
78. Vieta E., Suppes T., Eggens I., Persson I., Paulsson B., and Brecher M. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J. Affect. Disord. 109 3 (2008) 251-263
79. Vulink N.C.C., Fluitman S., Meinardi J.C.M., Westenberg H.G.M., and Denys D. Double-blind, randomized, placebo-controlled addition of quetiapine in non-refractory OCD patients. Eur. Neuropsychopharmacol. 17 (2007) S86-S87
80. Wang J.S., Zhu H.J., Markowitz J.S., Donovan J.L., and Devane C.L. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology 187 4 (2006) 415-423
81. Winter H.R., Devane C.L., Figueroa C., Ennis D.J., Hamer-Maansson J.E., Davis P.C., and Smith M.A. Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder. Human Psychopharmacology-Clinical and Experimental 22 7 (2007) 469-476
82. Wolfsperger M., Greil W., Rossler W., and Grohmann R. Pharmacological treatment of acute mania in psychiatric in-patients between 1994 and 2004. J. Affect. Disord. 99 1-3 (2007) 9-17
83. Yatham L.N., Grossman F., Augustyns I., Vieta E., and Ravindran A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania-international, double-blind, randomised controlled trial. Br. J, Psychiatry 182 (2003) 141-147